170 related articles for article (PubMed ID: 14657567)
21. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
[TBL] [Abstract][Full Text] [Related]
22. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
[TBL] [Abstract][Full Text] [Related]
23. Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases.
Wadkins RM; Morton CL; Weeks JK; Oliver L; Wierdl M; Danks MK; Potter PM
Mol Pharmacol; 2001 Aug; 60(2):355-62. PubMed ID: 11455023
[TBL] [Abstract][Full Text] [Related]
24. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38.
Stubdal H; Perin N; Lemmon M; Holman P; Bauzon M; Potter PM; Danks MK; Fattaey A; Dubensky T; Johnson L
Cancer Res; 2003 Oct; 63(20):6900-8. PubMed ID: 14583489
[TBL] [Abstract][Full Text] [Related]
25. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
[TBL] [Abstract][Full Text] [Related]
27. Modifications of human carboxylesterase for improved prodrug activation.
Hatfield JM; Wierdl M; Wadkins RM; Potter PM
Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1153-65. PubMed ID: 18721110
[TBL] [Abstract][Full Text] [Related]
28. Synthesis of a new class of camptothecin derivatives, the long-chain fatty acid esters of 10-hydroxycamptothecin, as a potent prodrug candidate, and their in vitro metabolic conversion by carboxylesterases.
Takayama H; Watanabe A; Hosokawa M; Chiba K; Satoh T; Aimi N
Bioorg Med Chem Lett; 1998 Mar; 8(5):415-8. PubMed ID: 9871589
[TBL] [Abstract][Full Text] [Related]
29. Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Gutova M; Shackleford GM; Khankaldyyan V; Herrmann KA; Shi XH; Mittelholtz K; Abramyants Y; Blanchard MS; Kim SU; Annala AJ; Najbauer J; Synold TW; D'Apuzzo M; Barish ME; Moats RA; Aboody KS
Gene Ther; 2013 Feb; 20(2):143-50. PubMed ID: 22402322
[TBL] [Abstract][Full Text] [Related]
30. Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
Sai K; Saito Y; Tatewaki N; Hosokawa M; Kaniwa N; Nishimaki-Mogami T; Naito M; Sawada J; Shirao K; Hamaguchi T; Yamamoto N; Kunitoh H; Tamura T; Yamada Y; Ohe Y; Yoshida T; Minami H; Ohtsu A; Matsumura Y; Saijo N; Okuda H
Br J Clin Pharmacol; 2010 Aug; 70(2):222-33. PubMed ID: 20653675
[TBL] [Abstract][Full Text] [Related]
31. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug.
Senter PD; Beam KS; Mixan B; Wahl AF
Bioconjug Chem; 2001; 12(6):1074-80. PubMed ID: 11716702
[TBL] [Abstract][Full Text] [Related]
32. Structural insights into CPT-11 activation by mammalian carboxylesterases.
Bencharit S; Morton CL; Howard-Williams EL; Danks MK; Potter PM; Redinbo MR
Nat Struct Biol; 2002 May; 9(5):337-42. PubMed ID: 11967565
[TBL] [Abstract][Full Text] [Related]
33. An overview of the recent progress in irinotecan pharmacogenetics.
Fujiwara Y; Minami H
Pharmacogenomics; 2010 Mar; 11(3):391-406. PubMed ID: 20235794
[TBL] [Abstract][Full Text] [Related]
34. In vitro activation of irinotecan to SN-38 by human liver and intestine.
Ahmed F; Vyas V; Cornfield A; Goodin S; Ravikumar TS; Rubin EH; Gupta E
Anticancer Res; 1999; 19(3A):2067-71. PubMed ID: 10470149
[TBL] [Abstract][Full Text] [Related]
35. Regulation of carboxylesterase-2 expression by p53 family proteins and enhanced anti-cancer activities among 5-fluorouracil, irinotecan and doxazolidine prodrug.
Xiao D; Yang D; Guo L; Lu W; Charpentier M; Yan B
Br J Pharmacol; 2013 Apr; 168(8):1989-99. PubMed ID: 23373735
[TBL] [Abstract][Full Text] [Related]
36. [Irinotecan pharmacokinetics].
Chabot GG; Robert J; Lokiec F; Canal P
Bull Cancer; 1998 Dec; Spec No():11-20. PubMed ID: 9932079
[TBL] [Abstract][Full Text] [Related]
37. Non-linear pharmacokinetics of irinotecan in mice.
Rouits E; Guichard S; Canal P; Chatelut E
Anticancer Drugs; 2002 Jul; 13(6):631-5. PubMed ID: 12172509
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme.
Gutova M; Najbauer J; Chen MY; Potter PM; Kim SU; Aboody KS
Curr Stem Cell Res Ther; 2010 Sep; 5(3):273-6. PubMed ID: 19951251
[TBL] [Abstract][Full Text] [Related]
39. Expression and characterization of a human carboxylesterase 2 splice variant.
Schiel MA; Green SL; Davis WI; Sanghani PC; Bosron WF; Sanghani SP
J Pharmacol Exp Ther; 2007 Oct; 323(1):94-101. PubMed ID: 17636009
[TBL] [Abstract][Full Text] [Related]
40. Metabolism of CPT-11. Impact on activity.
Rivory LP
Ann N Y Acad Sci; 2000; 922():205-15. PubMed ID: 11193896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
